SEC Form 4 · accession 0001225208-18-014477
Edwards Lifesciences Corp · EW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Huimin Wang
Officer — CVP, Japan & Intercontinental
Period of report
Oct 5, 2018
Accepted (ET)
Oct 9, 2018 · 6:01 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001099800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 5, 2018 | M | 3,800 | $42.725 | A | 81,665 | D | |
| Common StockF2 | Oct 5, 2018 | S | 3,800 | $152.7889 | D | 77,865 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Acquire) | $42.725 | Oct 5, 2018 | M | 3,800 | D | May 9, 2013 | May 8, 2019 | Common Stock | 3,800 | 15,600 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 15, 2018.
- F2This transaction was executed in multiple trades at prices ranging from $152.2692 to $152.90. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.